developed an 89Zr-radiolabeled fusion protein composed of an anti-albumin nanobody (Alb8) and anti-hepatocyte growth factor (HGF) nanobody (1E2 or 6E10) for both anti-cancer toxicity and PET imaging in vivo; targeting albumin is generally accepted to extend an antibody’s half-life by pH-dependent, FcRn-mediated intracellular recycling. Here, ALB is linked to cancer.